30
Jul

AstraZeneca has signed an agreement to pick up Almirall’s respiratory business for up to $2.1 billion, hoping to shoulder its way to the front of a blockbuster market for COPD treatments.

…read more

Source: AstraZeneca bets on respiratory growth with $2.1B Almirall deal

    

0 No comments